Eupraxia Pharmaceuticals (EPRX) Capital Expenditures (2023 - 2026)
Eupraxia Pharmaceuticals (EPRX) posted quarterly Capital Expenditures of -$326953.0 for Q1 2026, down 93.41% year-over-year from -$5.0 million in Q1 2025, and down 133.21% quarter-over-quarter from $984593.0 in Q4 2025.
Eupraxia Pharmaceuticals (EPRX) Capital Expenditures (2023 - 2026) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has reported Capital Expenditures for 4 consecutive years, with -$326953.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures fell 93.41% year-over-year to -$326953.0; the TTM figure through Mar 2026 stood at $431038.0 (up 842.81% YoY), while the FY2025 annual figure was $588947.0, up 465.06% from the prior year.
- Capital Expenditures slipped to -$326953.0 in Q1 2026 per EPRX's latest filing, from $984593.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $984593.0 in Q4 2025 and bottomed at -$326953.0 in Q1 2026.
- Historically, Capital Expenditures has averaged $33815.2 across 4 years, with a median of -$9602.0 in 2023.
- On a YoY basis, Capital Expenditures climbed as much as 499.85% in 2025 and fell as far as 2389.97% in 2025.
- Eupraxia Pharmaceuticals' Capital Expenditures stood at $97369.0 in 2023, then jumped by 68.57% to $164139.0 in 2024, then soared by 499.85% to $984593.0 in 2025, then plunged by 133.21% to -$326953.0 in 2026.
- Business Quant data shows EPRX's Capital Expenditures at -$326953.0 in Q1 2026, $984593.0 in Q4 2025, and -$60377.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Eupraxia Pharmaceuticals | 381.11 Mn | 379.51 Mn | - | -326,953.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -326,953.00 |
| Mar 31, 2026 | -326,953.00 |
| Dec 31, 2025 | 984,593.00 |
| Dec 31, 2025 | 984,593.00 |
| Sep 30, 2025 | -60,377.00 |
| Sep 30, 2025 | -60,377.00 |
| Jun 30, 2025 | -166,225.00 |
| Jun 30, 2025 | -166,225.00 |
| Mar 31, 2025 | -169,044.00 |
| Mar 31, 2025 | -169,044.00 |
| Dec 31, 2024 | 164,139.00 |
| Dec 31, 2024 | 164,139.00 |
| Sep 30, 2024 | -42,275.00 |
| Sep 30, 2024 | -42,275.00 |
| Jun 30, 2024 | -10,848.00 |
| Jun 30, 2024 | -10,848.00 |
| Mar 31, 2024 | -6,789.00 |
| Mar 31, 2024 | -6,789.00 |
| Dec 31, 2023 | 97,369.00 |
| Dec 31, 2023 | 97,369.00 |